Ocriplasmin injection showed high rate of success in select VMT patients

LISBON, Portugal — Real-life data of a selected, homogeneous group of patients with vitreomacular traction only, treated by a single injection of ocriplasmin, showed higher efficacy compared with MIVI-TRUST data. “We had an overall success rate, in terms of resolution of the traction, in 52% of the patients, compared with the 26% rate of the MIVI-TRUST. Patients with focal traction did even better, with a 61% success rate,” Peter Szurman, MD, said in an industry-sponsored symposium at the Controversies in Ophthalmology meeting.